Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6527011 | 0.92 | EPHB4 (0.94) | EPHB4 | |
| SCHEMBL5486801 | 0.90 | EPHB4 (1.00) | EPHB4 | |
| SCHEMBL5478632 | 0.89 | EPHB4 (1.00) | EPHB4 | |
| SCHEMBL5482549 | 0.89 | EPHB4 (1.00) | EPHB4 | |
| SCHEMBL5475471 | 0.89 | EPHB4 (1.00) | EPHB4 | |
| SCHEMBL5478639 | 0.88 | EPHB4 (0.86) | EPHB4 | |
| SCHEMBL5482521 | 0.87 | EPHB4 (0.85) | EPHB4 | |
| SCHEMBL5486306 | 0.87 | EPHB4 (1.00) | EPHB4 | |
| SCHEMBL5488557 | 0.86 | EPHB4 (1.00) | EPHB4 | |
| SCHEMBL5480341 | 0.85 | EPHB4 (0.85) | EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259164-B2 | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity | CGI PHARMACEUTICALS, INC. (US) | 2007-08-21 | — | — | US | claimed |
| US-20050085484-A1 | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2005-04-21 | — | — | US | claimed |
| US-7259164-B2 | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity | CGI PHARMACEUTICALS, INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259164-B2 | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity | CGI PHARMACEUTICALS, INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259164-B2 | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity | CGI PHARMACEUTICALS, INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-20050085484-A1 | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085484-A1 | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity | ERBB4, MAP4K4, EPHB4 | EPHB4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.